HC Wainwright Cuts GH Research (NASDAQ:GHRS) Price Target to $65.00

GH Research (NASDAQ:GHRS) had its price target lowered by equities researchers at HC Wainwright from $70.00 to $65.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 199.82% from the company’s previous close.

GHRS has been the topic of several other research reports. Cantor Fitzgerald boosted their target price on GH Research from $25.00 to $35.00 and gave the stock an “overweight” rating in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a research note on Tuesday, April 21st. Citigroup reiterated an “outperform” rating on shares of GH Research in a research report on Friday. Citizens Jmp dropped their price objective on GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a research note on Friday. Finally, Guggenheim set a $34.00 price objective on GH Research and gave the company a “buy” rating in a report on Tuesday, March 10th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.38.

GH Research Stock Up 1.4%

Shares of GHRS opened at $21.68 on Tuesday. The firm has a market capitalization of $1.49 billion, a PE ratio of -23.56 and a beta of 1.27. The firm has a 50-day moving average price of $17.27 and a 200 day moving average price of $15.59. GH Research has a 52-week low of $10.66 and a 52-week high of $24.66.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). On average, equities analysts expect that GH Research will post -1.52 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Lynx1 Capital Management LP boosted its stake in shares of GH Research by 27.5% during the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after acquiring an additional 1,854,238 shares in the last quarter. Avoro Capital Advisors LLC purchased a new stake in shares of GH Research during the fourth quarter valued at $22,860,000. Millennium Management LLC lifted its holdings in shares of GH Research by 324.1% during the third quarter. Millennium Management LLC now owns 863,602 shares of the company’s stock valued at $12,350,000 after purchasing an additional 659,957 shares during the last quarter. Troluce Capital Advisors LLC boosted its position in shares of GH Research by 165.4% in the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after purchasing an additional 617,260 shares during the period. Finally, RTW Investments LP increased its stake in GH Research by 6.5% in the 4th quarter. RTW Investments LP now owns 5,933,815 shares of the company’s stock worth $75,359,000 after purchasing an additional 364,251 shares in the last quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.